Browsing Bergen Open Research Archive by Author "Brenk, Ruth"
Now showing items 1-5 of 5
-
How To Design Selective Ligands for Highly Conserved Binding Sites: A Case Study Using N-Myristoyltransferases as a Model System
Kersten, Christian; Fleischer, Edmond; Kehrein, Josef; Borek, Christoph; Jaenicke, Elmar; Sotriffer, Christoph; Brenk, Ruth (Peer reviewed; Journal article, 2020)A model system of two related enzymes with conserved binding sites, namely N-myristoyltransferase from two different organisms, was studied to decipher the driving forces that lead to selective inhibition in such cases. ... -
Identification of a potential allosteric site of Golgi α-mannosidase II using computer-aided drug design
Irsheid, Lina; Wehler, Thomas; Borek, Christoph; Kiefer, Werner; Brenk, Ruth; Ortiz-Soto, Maria Elena; Seibel, Jurgen; Schirmeister, Tanja (Peer reviewed; Journal article, 2019-05-08)Golgi α-mannosidase II (GMII) is a glycoside hydrolase playing a crucial role in the N-glycosylation pathway. In various tumour cell lines, the distribution of N-linked sugars on the cell surface is modified and correlates ... -
In silico identification and experimental validation of hits active against KPC-2 β-lactamase
Klein, Raphael; Linciano, Pasquale; Celenza, Guiseppe; Bellio, Pierangelo; Papaioannou, Sofia; Blazques, Jesus; Cendron, Laura; Brenk, Ruth; Tondi, Donatella (Peer reviewed; Journal article, 2018-11-29)Bacterial resistance has become a worldwide concern, particularly after the emergence of resistant strains overproducing carbapenemases. Among these, the KPC-2 carbapenemase represents a significant clinical challenge, ... -
Targeting the Class A Carbapenemase GES-5 via Virtual Screening
Klein, Raphael; Cendron, Laura; Montanari, Maria; Bellio, Pierangelo; Celenza, Giuseppe; Maso, Lorenzo; Tondi, Donatella; Brenk, Ruth (Journal article; Peer reviewed, 2020)The worldwide spread of β-lactamases able to hydrolyze last resort carbapenems contributes to the antibiotic resistance problem and menaces the successful antimicrobial treatment of clinically relevant pathogens. Class A ... -
To hit or not to hit, that is the question -genome-wide structure-based druggability predictions for pseudomonas aeruginosa proteins
Sarkar, Aurijit; Brenk, Ruth (Peer reviewed; Journal article, 2015-09-11)Pseudomonas aeruginosa is a Gram-negative bacterium known to cause opportunistic infections in immune-compromised or immunosuppressed individuals that often prove fatal. New drugs to combat this organism are therefore ...